NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Sanofi Pasteur, a Sanofi Company
Conditions: Influenza (Healthy Volunteers)
Interventions: Quadrivalent Influenza Vaccine, High-Dose Quadrivalent Influenza Vaccine
Countries: Finland, Germany
The primary objective of the study is to estimate the reporting rate of suspected Adverse Drug Reactions (ADRs) occurring within 7 days following routine vaccination with VaxigripTetra® and Efluelda®, respectively, during the Northern Hemisphere (NH) influenza season 2021/22. The secondary objectives of the study are: * To estimate the reporting rates of suspected ADRs occurring within 7 days following routine vaccination with VaxigripTetra® according to the pre-defined age groups. * To estimate the reporting rates of serious suspected ADRs after vaccination with VaxigripTetra®, and Efluelda®, respectively, at any time following vaccination, within the Enhanced Passive Safety Surveillance (EPSS) period. * To compare vaccinees' reporting rates of suspected ADRs observed during the NH influenza season 2021/22.
Sex: ALL
Age: 6 Months to —
Healthy volunteers: Yes
Study type: OBSERVATIONAL
Individuals who approach the site for vaccination and agree to receive a vaccination card will be included and vaccinated with the respective vaccine brand according to the country of their location, recommendations for the individual vaccines as well as national recommendations.
- Helsinki, Finland
- Jyväskylä, Finland
- Kuopio, Finland
- Tampere, Finland
- Turku, Finland
- Blankenhain, Germany
- Bochum, Germany
- Donaueschingen, Germany
- Düsseldorf, Germany
- Frankfurt am Main, Germany
- Fulda, Germany
- Grafenrheinfeld, Germany
- Haar, Germany
- Hamburg, Germany
- Wendelstein, Germany